| No patients | No CR (%) | p | 5 yr-EFS | p | 5 yr-OS | p |
---|---|---|---|---|---|---|---|
Whole cohort | N = 36 | 26 (72%) |  | 33.3 ± 7.9 |  | 47.2 ± 8.3 |  |
Inclusion period | Â | Â | Â | Â | Â | Â | Â |
< July, 1996 | 15 | 9 (60%) |  | 20 ± 10 |  | 33 ± 12 |  |
> July, 1996 | 21 | 17 (81%) | 0.26 | 43 ± 11 | 0.13 | 57 ± 11 | 0.31 |
Age (years) | Â | Â | Â | Â | Â | Â | Â |
<10 | 23 | 20 (87%) |  | 48 ± 10 |  | 61 ± 10 |  |
≥ 10 | 13 | 6 (46%) | 0.018 | 15 ± 10 | 0.01 | 23 ± 12 | 0.006 |
WBC (/mm 3 ) | Â | Â | Â | Â | Â | Â | Â |
<50,000 | 21 | 17 (81%) |  | 33 ± 10 |  |  |  |
≥ 50,000 | 15 | 9 (60%) | 0.26 | 33 ± 12 | 0.54 |  | 0.91 |
<100,000 | 26 | 22 (85%) |  | 42 ± 10 |  | 58 ± 10 |  |
≥ 100,000 | 10 | 4 (40%) | 0.014 | 10 ± 9 | 0.003 | 20 ± 13 | 0.03 |
Response to steroid (+3 drug intra-thecal injection) at D8 | Â | Â | Â | Â | Â | Â | Â |
poor (≥ 1000 blasts/mm3) | 5 | 2 (40%) |  | 20 ± 18 |  | 20 ± 18 |  |
good(<1000 blasts/mm3) | 31 | 24 (77%) | 0.12 | 35 ± 9 | 0.33 | 52 ± 9 | 0.19 |
Response to chemotherapy evaluated on D21 | Â | Â | Â | Â | Â | Â | Â |
M1(≤ 5% blasts) | 21 | 20 (95%) |  | 43 ± 11 |  | 62 ± 11 |  |
M2+M3 (>5%–25% and >25% blasts) | 15 | 6 (40%) | 0.0004 | 20 ± 10 | 0.18 | 27 ± 11 | 0.06 |
Age, D21 response and WBC | Â | Â | Â | Â | Â | Â | Â |
Age<10 and D21 M1 and WBC count<100,000 | 14 | 14 (100%) |  | 57 ± 13 |  | 79 ± 11 |  |
Others | 22 | 12 (55%) | 0.003 | 18 ± 8 | 0.002 | 27 ± 9 | 0.003 |